T.L. Feenstra
T.L. Feenstra
Associate Professor of PharmacoEconomics, Groningen University
Verified email at - Homepage
Cited by
Cited by
Lifetime medical costs of obesity: prevention no cure for increasing health expenditure
PHM van Baal, JJ Polder, GA de Wit, RT Hoogenveen, TL Feenstra, ...
PLoS medicine 5 (2), e29, 2008
The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands
TL Feenstra, MLL van GENUGTEN, RT Hoogenveen, EF Wouters, ...
American journal of respiratory and critical care medicine 164 (4), 590-596, 2001
A decision chart for assessing and improving the transferability of economic evaluation results between countries
R Welte, T Feenstra, H Jager, R Leidl
Pharmacoeconomics 22 (13), 857-876, 2004
AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users
P Vemer, IC Ramos, GAK Van Voorn, MJ Al, TL Feenstra
Pharmacoeconomics 34 (4), 349-361, 2016
Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach
M Hoogendoorn, RT Hoogenveen, MP Rutten-van Mölken, J Vestbo, ...
European respiratory journal 37 (3), 508-515, 2011
Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study
TL Feenstra, HH Hamberg-van Reenen, RT Hoogenveen, ...
Value in health 8 (3), 178-190, 2005
Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD
M Hoogendoorn, TL Feenstra, RT Hoogenveen, ...
Thorax 65 (8), 711-718, 2010
A dynamic population model of disease progression in COPD
M Hoogendoorn, M Rutten-van Mölken, RT Hoogenveen, ...
European Respiratory Journal 26 (2), 223-233, 2005
Association between lung function and exacerbation frequency in patients with COPD
M Hoogendoorn, TL Feenstra, RT Hoogenveen, M Al, ...
International journal of chronic obstructive pulmonary disease 5, 435, 2010
Cost-effectiveness of lifestyle modification in diabetic patients
MAM Jacobs-van der Bruggen, PH van Baal, RT Hoogenveen, ...
Diabetes care 32 (8), 1453-1458, 2009
Unrelated medical costs in Life-Years gained
DR Rappange, PHM van Baal, NJA van Exel, TL Feenstra, FFH Rutten, ...
Pharmacoeconomics 26 (10), 815-830, 2008
Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice
M Hoogendoorn, TL Feenstra, TRJ Schermer, AE Hesselink, ...
Respiratory medicine 100 (1), 83-86, 2006
Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a ‘perfect’cost–utility ratio
PHM Van Baal, TL Feenstra, RT Hoogenveen, G Ardine de Wit, ...
Health economics 16 (4), 421-433, 2007
Computer modeling of diabetes and its transparency: a report on the eighth mount hood challenge
AJ Palmer, L Si, M Tew, X Hua, MS Willis, C Asseburg, P McEwan, J Leal, ...
Value in Health 21 (6), 724-731, 2018
Projecting the COPD population and costs in England and Scotland: 2011 to 2030
S McLean, M Hoogendoorn, RT Hoogenveen, TL Feenstra, S Wild, ...
Scientific reports 6 (1), 1-10, 2016
Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus
SMC Vijgen, M Hoogendoorn, CA Baan, GA de Wit, W Limburg, ...
Pharmacoeconomics 24 (5), 425-441, 2006
Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation
RT Hoogenveen, PHM van Baal, HC Boshuizen, TL Feenstra
Cost effectiveness and resource allocation 6 (1), 1-15, 2008
Increasing tobacco taxes: a cheap tool to increase public health
PHM van Baal, WBF Brouwer, RT Hoogenveen, TL Feenstra
Health Policy 82 (2), 142-152, 2007
Economic evaluation and the postponement of health care costs
PHM van Baal, TL Feenstra, JJ Polder, RT Hoogenveen, WBF Brouwer
Health economics 20 (4), 432-445, 2011
Decision makers’ views on health care objectives and budget constraints: results from a pilot study
MJ Al, T Feenstra, WBF Brouwer
Health Policy 70 (1), 33-48, 2004
The system can't perform the operation now. Try again later.
Articles 1–20